120 related articles for article (PubMed ID: 21113600)
21. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
22. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
25. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of Cancer Stem Cell Markers OCT4 and NANOG Predicts Poor Prognosis in Renal Cell Carcinomas.
Rasti A; Mehrazma M; Madjd Z; Abolhasani M; Saeednejad Zanjani L; Asgari M
Sci Rep; 2018 Aug; 8(1):11739. PubMed ID: 30082842
[TBL] [Abstract][Full Text] [Related]
27. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.
Saeednejad Zanjani L; Madjd Z; Abolhasani M; Andersson Y; Rasti A; Shariftabrizi A; Asgari M
Exp Mol Pathol; 2017 Oct; 103(2):218-228. PubMed ID: 29050853
[TBL] [Abstract][Full Text] [Related]
28. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.
Hoffmann NE; Sheinin Y; Lohse CM; Parker AS; Leibovich BC; Jiang Z; Kwon ED
Cancer; 2008 Apr; 112(7):1471-9. PubMed ID: 18260086
[TBL] [Abstract][Full Text] [Related]
29. Stem cell markers aldehyde dehydrogenase type 1 and nestin expressions in renal cell cancer.
Ozbek E; Calik G; Otunctemur A; Aliskan T; Cakir S; Dursun M; Somay A
Arch Ital Urol Androl; 2012 Mar; 84(1):7-11. PubMed ID: 22649953
[TBL] [Abstract][Full Text] [Related]
30. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases.
Amin MB; Corless CL; Renshaw AA; Tickoo SK; Kubus J; Schultz DS
Am J Surg Pathol; 1997 Jun; 21(6):621-35. PubMed ID: 9199639
[TBL] [Abstract][Full Text] [Related]
31. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging.
Yu KJ; Keskin SK; Meissner MA; Petros FG; Wang X; Borregales LD; Gu C; Tamboli P; Matin SF; Wood CG; Karam JA
Cancer; 2018 Oct; 124(20):4023-4031. PubMed ID: 30276798
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.
Tickoo SK; dePeralta-Venturina MN; Harik LR; Worcester HD; Salama ME; Young AN; Moch H; Amin MB
Am J Surg Pathol; 2006 Feb; 30(2):141-53. PubMed ID: 16434887
[TBL] [Abstract][Full Text] [Related]
33. Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?
Ng KL; Del Vecchio SJ; Samaratunga H; Morais C; Rajandram R; Vesey DA; Wood ST; Gobe GC
Pathology; 2018 Aug; 50(5):504-510. PubMed ID: 29970253
[TBL] [Abstract][Full Text] [Related]
34. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.
Horstmann M; Merseburger AS; von der Heyde E; Serth J; Wegener G; Mengel M; Feil G; Hennenlotter J; Nagele U; Anastasiadis A; Bokemeyer C; Stenzl A; Kuczyk M
J Cancer Res Clin Oncol; 2005 Nov; 131(11):715-22. PubMed ID: 16080018
[TBL] [Abstract][Full Text] [Related]
35. MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma.
Leroy X; Zerimech F; Zini L; Copin MC; Buisine MP; Gosselin B; Aubert JP; Porchet N
Am J Clin Pathol; 2002 Jul; 118(1):47-51. PubMed ID: 12109855
[TBL] [Abstract][Full Text] [Related]
36. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
[TBL] [Abstract][Full Text] [Related]
37. Angiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP.
Lv M; Li S; Luo C; Zhang X; Shen Y; Sui YX; Wang F; Wang X; Yang J; Liu P; Yang J
Oncotarget; 2016 Mar; 7(11):12393-403. PubMed ID: 26848622
[TBL] [Abstract][Full Text] [Related]
38. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53.
Leroy X; Zini L; Buob D; Ballereau C; Villers A; Aubert S
Arch Pathol Lab Med; 2007 Jan; 131(1):102-6. PubMed ID: 17227108
[TBL] [Abstract][Full Text] [Related]
39. Nuclear EGFR characterize still controlled proliferation retained in better differentiated clear cell RCC.
Ahel J; Dordevic G; Markic D; Mozetic V; Spanjol J; Grahovac B; Stifter S
Med Hypotheses; 2015 Aug; 85(2):183-5. PubMed ID: 25959864
[TBL] [Abstract][Full Text] [Related]
40. Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.
Kruck S; Bedke J; Hennenlotter J; Ohneseit PA; Kuehs U; Senger E; Sievert KD; Stenzl A
Oncol Rep; 2010 Jan; 23(1):159-63. PubMed ID: 19956876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
